

P-24875

Documents referenced by Teva Defendants in response to Interrogatory No. 29 of their July 23, 2020 Supplemental Responses to People's Second Set of Interrogatories, served in *The People v. State of California v. Purdue Pharma L.P. et al*, Orange County California Superior Court Case No. 30-2014-00725287-CU-BT-CXC - Teva Defendants opioid sales and receivable data (1).

PLAINTIFFS TRIAL
EXHIBIT

P-24875a

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

SUPPLEMENTAL RESPONSES AND OBJECTIONS TO INTERROGATORIES

INTERROGATORY NO. 29:

Identify each OPIOID you ever sold in California, and for each OPIOID identified state on a monthly and annual basis the number of individual units sold (e.g. pills, lozenges, lollipop sticks, transdermal patches) and market share. If this information is not available for California, then provide nationally.

RESPONSE TO INTERROGATORY NO. 29:

The Teva Defendants reassert and incorporate each of the foregoing General Objections

1 set forth above into this response. The Teva Defendants further object to this Request to the
2 extent that it seeks to impose obligations upon the Teva Defendants broader than or inconsistent
3 with the California Code of Civil Procedure. The Teva Defendants further object on the grounds
4 that the Interrogatory is vague and ambiguous, overbroad, unduly burdensome, and not
5 reasonably calculated to lead to the discovery of admissible evidence. The Teva Defendants
6 further object to the Interrogatory as not reasonably limited as to time or scope. The Teva
7 Defendants further object to this Interrogatory as overbroad and unduly burdensome because it
8 purports to encompass, without limitation “each” such OPIOID ever sold in California. The Teva
9 Defendants object to this Interrogatory on the grounds that “units” and “market share” are
10 undefined, vague, ambiguous and overbroad. The Teva Defendants object to this Interrogatory as
11 not reasonably limited in time or scope.

12 Subject to and without waiving the foregoing objections, the Teva Defendants respond as
13 follows: The Teva Defendants refer Plaintiff to Attachment A, which identifies each opioid
14 product sold by the Teva Defendants nationally. The Teva Defendants further refer Plaintiff to
15 documents previously produced by the Teva Defendants in this litigation that contain information
16 responsive to this Interrogatory, including:

- 17 • Actiq sales data from 2001–Q1 2012, which may be found at
18 TEVA_MDL_A_06447382;
- 19 • Fentora sales data from 2006–Q1 2012, which may be found at
20 TEVA_MDL_A_02419958;
- 21 • Actiq and Fentora sales data from Q2 2012– Q1 2018, which may be found at
22 TEVA_MDL_A_02401117; and
- 23 • Data regarding direct shipments and/or direct sales to pharmacies or pharmacy
24 distribution centers, including NDC data, volume, and the pharmacy or pharmacy
25 distribution center, which may be found at TEVA_MDL_A_02416192 and
26 TEVA_MDL_A_02416205.
- 27 • Net sales data from 2012–2017 for generic opioid products may be found at
28 TEVA_MDL_A_02416208 and TEVA_MDL_02419959;

- 1 • Accounts receivable transaction level data from 2008–2016 for generic opioid
- 2 products may be found at TEVA_MDL_A_02419966, TEVA_MDL_A_02419967,
- 3 TEVA_MDL_A_02419968, and TEVA_MDL_A_02419964;
- 4 • Accounts receivable transaction level data from Q2 2017–June 2018, which may be
- 5 found at TEVA_MDL_A_02419965;
- 6 • Accounts receivable transaction level data from 2013–2017 (Q1), which may be found
- 7 at TEVA_MDL_A_02419969, TEVA_MDL_A_02419963 and
- 8 TEVA_MDL_A_02419960;
- 9 • Additional summary sales data by unit (not dollar value) from 2011 to 2017, which
- 10 may be found at TEVA_MDL_A_02419962;
- 11 • Indirect sales data from 2006–Q2 2014, which may be found at:¹¹
- 12 • TEVA_MDL_A_07869902 - TEVA_MDL_A_07876853;
- 13 • TEVA_MDL_A_07876854 - TEVA_MDL_A_07880642;
- 14 • TEVA_MDL_A_07880643 - TEVA_MDL_A_07885149;
- 15 • TEVA_MDL_A_07885150 - TEVA_MDL_A_07889184;
- 16 • TEVA_MDL_A_07889185 - TEVA_MDL_A_07889288;
- 17 • TEVA_MDL_A_07889289 - TEVA_MDL_A_07901019;
- 18 • TEVA_MDL_A_07901020 - TEVA_MDL_A_07907288;
- 19 • TEVA_MDL_A_07907289 - TEVA_MDL_A_07914957;
- 20 • TEVA_MDL_A_07914958 - TEVA_MDL_A_07921676;
- 21 • TEVA_MDL_A_07921677 - TEVA_MDL_A_07921925;

22

23 ¹ Watson Laboratories, Inc., Actavis LLC, and Actavis Pharma, Inc. f/k/a Watson Pharma, Inc.
 24 (“Teva-Acquired Actavis Entities”) cannot verify the accuracy or completeness of the “indirect
 25 raw sales data” because of the form of the data as transferred from Allergan to Teva
 26 Pharmaceuticals USA, Inc. (“Teva USA”) when Teva USA acquired the Teva-Acquired Actavis
 27 Entities. As a result of multiple acquisitions over time, even before the acquisition from Allergan,
 28 the Teva-Acquired Actavis Entities were an aggregation of a number of companies that all had
 different systems and processes to record, track and report their financial information, inclusive of
 product sales information. Additionally, within the Teva-Acquired Actavis Entities there were
 system changes that occurred. Although Teva USA acquired certain legal entities and systems as
 a result of its acquisition of the Teva-Acquired Actavis Entities, this business did not have stand-
 alone records. Therefore, the Teva-Acquired Actavis Entities have no means by which to verify
 the completeness or accuracy of this information.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

- TEVA_MDL_A_07921926 - TEVA_MDL_A_07921926;
- TEVA_MDL_A_07921927 - TEVA_MDL_A_07921927;
- TEVA_MDL_A_07921928 - TEVA_MDL_A_07928168; and
- TEVA_MDL_A_07928169 - TEVA_MDL_A_07937356;
- Indirect sales data from Q2 2014–Q1 2017, which may be found at:
 - TEVA_MDL_A_08637273;
 - TEVA_MDL_A_08637274;
 - TEVA_MDL_A_08637275;
 - TEVA_MDL_A_08637276; and
 - TEVA_MDL_A_08637277; and
- Direct sales data, which may be found at TEVA_MDL_A_08637279.